Cargando…
Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non–Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial
IMPORTANCE: Treatment of locally advanced non–small cell lung cancer (NSCLC) remains challenging. The rationale of combining a cyclooxygenase 2 (COX-2) inhibitor with concurrent chemoradiation (CCRT) was based on results of preclinical research and prospective clinical studies; however, no randomize...
Autores principales: | Bi, Nan, Liang, Jun, Zhou, Zongmei, Chen, Dongfu, Fu, Zhixue, Yang, Xu, Feng, QinFu, Hui, Zhouguang, Xiao, Zefen, Lv, Jima, Wang, Xiaozhen, Zhang, Tao, Wang, Xin, Deng, Lei, Wang, Wenqing, Wang, Jingbo, Liu, Lipin, Hu, Chen, Wang, Luhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991217/ https://www.ncbi.nlm.nih.gov/pubmed/31851351 http://dx.doi.org/10.1001/jamanetworkopen.2019.18070 |
Ejemplares similares
-
Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis()()()
por: Wang, Jingbo, et al.
Publicado: (2018) -
The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019) -
A prospective comparative study between concurrent chemoradiation with brachytherapy boost with concurrent chemoradiation alone in locally advanced cancer esophagus
por: Tudu, Rajanigandha
Publicado: (2020) -
Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial
por: Fu, Zhixue, et al.
Publicado: (2020) -
Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial
por: Bi, Nan, et al.
Publicado: (2020)